CYP3A4 and prostate cancer: Docetaxel clearance in prostate cancer patients has been reported as castration-dependent, with castrated men experiencing a 100% increase in clearance and a two-fold reduction in area under the curve, despite unchanged hepatic CYP3A4 activity.